Group 1 - The establishment of the ETHK building marks a significant milestone for the company, representing the physical realization of its ETHK blockchain financial ecosystem strategy and positioning Nanjing as a global hub for Real World Asset (RWA) technology [1][4][14] - The RWA sector is transitioning from concept validation to large-scale application, with a projected total value locked (TVL) of $12.5 billion by June 2025, reflecting a 124% increase from 2024 [4] - The ETHK building will serve as a core base for RWA digital technology research and ecosystem empowerment, housing over 5,000 technical experts and various research facilities [7][14] Group 2 - The company has signed strategic cooperation agreements with four enterprises, including a $1.5 billion RWA tokenization deal with Chuangsheng Group, integrating six core innovative drug pipeline assets into its U.S. entity [8][13] - The partnerships aim to create a comprehensive ecosystem from biopharmaceutical innovation to legal compliance, enhancing the efficiency of asset value discovery and circulation through digitalization [13][14] - The company's "so-in-so" model aims to build a top-tier global trading ecosystem for RWA across multiple industries, providing a one-stop solution for asset digital transformation [13][14] Group 3 - The launch of the ETHK building and the strategic partnerships signify the company's transition into a scalable phase of its ETHK blockchain financial ecosystem strategy [14][15] - The RWA tokenization path chosen by the company is seen as forward-looking, with predictions estimating the global RWA market to reach $16.1 trillion by 2030, accounting for 10% of global GDP [15] - The company's "altruistic" approach allows partners to optimize their asset structures and innovate financing models, facilitating the development of cutting-edge therapies and improving patient accessibility [15][16]

Group 1 - A new asset paradigm is emerging globally, driven by the tokenization of Real World Assets (RWA) using blockchain technology, enabling continuous global liquidity and financing [1][17] - The ETHK Building, launched by Huajian Medical in Nanjing, is the world's first RWA technology base, marking a significant step in the large-scale implementation of RWA technology in China [3][8] - The ETHK Building spans approximately 70,000 square meters, with the main building covering 35,000 square meters, making it the largest and most comprehensive RWA research and innovation base globally [3][7] Group 2 - The establishment of the ETHK Building addresses the dual challenges of technical infrastructure and regulatory frameworks that have hindered the large-scale implementation of RWA [3][8] - The building is designed as a dual-purpose infrastructure, serving as both a center for R&D and a base for trusted technology development and output [3][7] - The facility is expected to gather over 5,000 technical experts and engineers, forming one of the strongest RWA research teams globally [7] Group 3 - Huajian Medical's "ETHK Global RWA Trading - Exchange within an Exchange" model aims to fill the service gap in China's RWA market, providing a comprehensive solution for asset selection, structural design, compliance issuance, and liquidity management [8][9] - This model is particularly valuable in the healthcare sector, facilitating innovative financing for drug development and global market expansion [9][10] Group 4 - Huajian Medical has entered a phase of scaling its "Exchange within an Exchange" model, signing strategic cooperation agreements with four key partners across various sectors, including pharmaceuticals and legal compliance [9][10] - The collaboration with Chuangsheng Group involves the tokenization of innovative drug pipeline assets, with a total valuation exceeding $1.5 billion, representing cutting-edge research in cancer treatment [10] Group 5 - The launch of the RWA Protocol White Paper addresses key challenges in the current financial system, focusing on creating a foundational protocol for the issuance and trading of real-world assets [10][15] - The RWA Protocol aims to enhance settlement efficiency, transparency, and compliance in capital markets, facilitating cross-border asset allocation [15] Group 6 - Huajian Medical's strategy aligns with national policies promoting the market-oriented operation and securitization of intellectual property, as highlighted in recent government initiatives [16] - The global RWA market is projected to reach $16.1 trillion by 2030, representing 10% of global GDP, indicating significant growth potential [16] Group 7 - The completion of the ETHK Building symbolizes a new financial paradigm and showcases China's innovative capabilities in integrating blockchain with the real economy [17] - As more assets are tokenized through RWA, a more open, efficient, and inclusive global asset allocation era is anticipated, with Huajian Medical leading the charge [17]

Core Viewpoint - The cryptocurrency concept stocks in the Hong Kong market have seen significant gains this year, with Huajian Medical (01931.HK) experiencing a remarkable increase of nearly 490% since mid-July, driven by its strategic pivot into the Web3 space [2][4]. Group 1: Company Strategy and Developments - Huajian Medical, traditionally an IVD (in vitro diagnostics) distributor, has made a bold move into the Web3 sector, announcing plans to establish the "IVDNewCo Exchange" focused on tokenizing real-world assets (RWA) [3][4]. - The company is actively pursuing regulatory compliance for its Web3 initiatives, including applications for stablecoin licenses in Hong Kong and the U.S., and plans to acquire additional licenses in Europe and Singapore [4][5]. - A significant brand upgrade has been initiated, including a new logo and website, to align with the company's Web3 exchange strategy [7]. Group 2: Partnerships and Collaborations - Huajian Medical has entered into a strategic partnership with BGI to create an innovation drug intellectual property tokenization fund, which will invest in projects under the NewCo + RWA Web3 exchange model [8]. - A collaboration with HashKey Group aims to enhance the company's digital asset management capabilities and explore synergies between crypto assets and medical innovation [8]. - The company announced a strategic acquisition of a 20.31% stake in Guofu Quantum (00290.HK) to deepen collaboration in the RWA exchange ecosystem [9]. Group 3: Financial Performance - Despite the stock price surge, Huajian Medical's financial performance has been declining, with a reported revenue of 1.27 billion RMB for the first half of 2025, down 6.2% year-on-year, and a significant drop in net profit by 68.8% [14][15]. - The company's earnings per share fell from 9.27 RMB to 2.41 RMB in the same period, indicating challenges in maintaining profitability amidst strategic shifts [15]. Group 4: Market Context and Future Outlook - The Hong Kong market is increasingly embracing Web3 innovations, with a clear trend towards compliance and ecosystem development, positioning Huajian Medical to potentially benefit from this trend [16]. - The company's recent collaborations and strategic moves may help improve its financial performance, although skepticism remains among investors regarding the sustainability of its stock price increase [14][16].

Core Viewpoint - The strategic cooperation agreement between Huajian Medical and Chuangsheng Group aims to explore the tokenization of innovative drug pipeline assets valued at over $1.5 billion, focusing on six major oncology drug pipelines [1][2]. Group 1: Strategic Cooperation Details - Huajian Medical and Chuangsheng Group signed a strategic cooperation agreement to jointly explore the tokenization of innovative drug pipeline assets [1]. - The collaboration involves six innovative oncology drug pipelines, including TST003, TST005, TST786, and three preclinical antibody-drug conjugates TST105, TST106, and TST013 [1]. - These pipelines utilize advanced technologies such as bispecific antibodies, trispecific antibodies, ADCs, and fusion proteins, showcasing global innovation or best-in-class potential [1]. Group 2: Technological and Financial Aspects - Huajian Medical will provide a comprehensive technological solution covering digital initiation, trusted on-chain processes, compliant issuance, and liquidity integration for the pipeline assets [1]. - The cooperation is expected to lock in the R&D value of high-value pipelines, provide new channels for global capital allocation, and accelerate therapy accessibility [2].

Core Insights - The strategic cooperation agreement between Huajian Medical and Transcenta Holding aims to explore the potential RWA tokenization of six core innovative drug pipeline assets valued at over $1.5 billion, representing cutting-edge research in the global oncology treatment field [1][2] - This collaboration marks a significant milestone in the integration of technology and finance, as it represents the first issuance of high-value innovative drug intellectual property assets in RWA form in the capital market [1][2] Summary by Sections Strategic Cooperation - Huajian Medical and its subsidiaries have entered into a strategic cooperation agreement with Transcenta Holding and its subsidiaries to explore RWA tokenization of innovative drug pipeline assets [1] - The six core assets involved are TST003, TST005, TST786, TST105, TST106, and TST013, which are integrated into Transcenta Oncology Inc. in the U.S. [1] RWA Tokenization Benefits - The RWA tokenization aims to lock in the research value of high-value pipelines, allowing issuers to efficiently activate top pipeline assets at various clinical stages without diluting equity [2] - It provides a new channel for global capital allocation, offering professional investors a transparent, compliant, and efficient opportunity to invest in cutting-edge innovative drug intellectual property assets [2] - The innovative financing model is expected to accelerate the development of advanced therapies, ultimately benefiting global patients and addressing urgent unmet medical needs [2] Future Growth and Collaboration - The collaboration is anticipated to generate significant synergies, injecting strong momentum into the sustainable business growth and financial performance of the group [2] - The group will work closely with Transcenta to ensure the successful implementation of the project to high standards [2]

Core Insights - The strategic cooperation agreement between Huajian Medical and Transcenta Holding aims to explore the potential tokenization of six innovative drug pipeline assets valued at over $1.5 billion, marking a significant milestone in the integration of technology and finance in the pharmaceutical sector [1][2] Group 1: Strategic Cooperation - Huajian Medical and its subsidiaries have entered into a strategic cooperation agreement with Transcenta Holding and its subsidiaries to collaborate on the potential RWA tokenization of innovative drug pipeline assets [1] - The six core innovative drug pipeline assets include TST003, TST005, TST786, TST105, TST106, and TST013, which are integrated into Transcenta Oncology Inc. (US) [1] Group 2: RWA Tokenization Benefits - The tokenization process aims to lock in the research value of high-value pipelines, allowing issuers to efficiently activate top pipeline assets at various clinical stages without diluting equity [2] - It provides a new channel for global capital allocation, offering professional investors a transparent and compliant opportunity to invest in cutting-edge innovative drug intellectual property assets [2] - The innovative financing model is expected to accelerate the development of advanced therapies, ultimately benefiting global patients and addressing urgent unmet medical needs [2] Group 3: Future Growth and Collaboration - The collaboration is anticipated to generate significant synergies, injecting strong momentum into the sustainable business growth and financial performance of the group [2] - The group will work closely with Transcenta to ensure the successful implementation of the project to high standards [2]

Core Viewpoint - The strategic cooperation agreement between Huajian Medical and Chuangsheng Group-B marks a significant milestone in the integration of technology and finance, focusing on the tokenization of innovative drug pipeline assets valued at over $1.5 billion [1] Group 1: Strategic Cooperation - Huajian Medical and its subsidiaries ETHK Inc and ETHK HOLDINGS LIMITED have entered into a strategic cooperation agreement with Chuangsheng Group-B and its subsidiary Transcenta Oncology Inc. [1] - The agreement involves the integration of six core innovative drug pipeline assets into Transcenta Oncology Inc. [1] Group 2: Asset Valuation and Technology Solutions - The total valuation of the integrated assets exceeds $1.5 billion, representing cutting-edge research directions and high technical barriers in the global oncology treatment field [1] - The group will provide a comprehensive technical solution covering digital initiation, trusted on-chain processes, compliant issuance, and liquidity connection for these pipeline assets [1] Group 3: Market Impact - This cooperation signifies the official launch of high-value innovative drug intellectual property assets in the capital market in the form of RWA, highlighting a milestone event in the deep integration of technology and finance [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公 司） （股份代號：1931） 自願性公告 與 創 勝 集 團 醫 藥 有 限 公 司（06628.HK）簽 署 涉15億美元 創新藥管線資產RWA代幣化之戰略合作協議 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 的 最 新 資 料。 一、合作概況與六大創新藥管線亮點 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，本 公 司 及 本 公 司 附 屬 公 司ETHK Inc及 ETHK HOLDINGS LIMITED與創勝集團醫藥有限公司Transcenta ...

Core Insights - The completion of the ETHK Building in Nanjing marks the establishment of the world's first core base focused on the digitalization of Real World Assets (RWA) technology, serving as a strong response to market skepticism regarding RWA's viability [1][4] - The building symbolizes a strategic transformation for the company, transitioning its brand focus from "IVD" to "ETHK Labs," highlighting its role as an enabler of global digital industry innovation and blockchain financial infrastructure [1][4] Group 1: Strategic Leap - The announcements made by the company on September 19 signify a critical leap from conceptual leadership to large-scale physical R&D and implementation [3] - The ETHK Building is not just a commercial property; it serves dual foundational missions: as a hub for physical R&D and collaborative innovation, and as a credible technology development and output infrastructure [4] Group 2: Addressing Challenges - RWA technology, which tokenizes real-world assets for blockchain integration, is becoming a vital bridge between traditional and digital finance, with a total on-chain market value of $25.93 billion as of August 15, 2025, and a 11.86% increase in asset holders [5] - The potential of RWA is hindered by several core bottlenecks, including public chain performance limitations, funding barriers between traditional and crypto worlds, complex cross-border regulations, and general liquidity issues [5] Group 3: Ecosystem Empowerment - The company's innovative "ETHK Global RWA Exchange within an Exchange" business model provides top-tier technical infrastructure and compliance support to leading enterprises across various industries, allowing for rapid entry into different sectors with strong replicability and scalability [6] - The establishment of the ETHK Building provides a physical anchor to address trust issues in the RWA sector, demonstrating the company's commitment to advancing its blockchain financial ecosystem strategy [6] Group 4: Collaborative Advantage - The company's RWA ecosystem strategy is driven by the belief that technology should serve the public good, aiming to facilitate the efficient and compliant circulation of high-quality global assets [10] - The collaboration with Renhe Pharmaceutical to establish the world's first OTC vertical RWA exchange reflects the company's innovative business model, providing tailored solutions for asset digitization and capital structure optimization [9][10] - The choice of Nanjing as the core base for RWA technology underscores strategic considerations, as the region is a hub for the biopharmaceutical industry with a mature ecosystem [9] Group 5: Industry Impact - The ETHK Building stands as a physical benchmark for the industry, representing the maturation of the RWA sector from virtual concepts to tangible, scalable implementations [11] - The partnership with Renhe Pharmaceutical is expected to introduce a "digital License-in/Out" model, breaking down traditional barriers to cross-border collaboration and enhancing innovation efficiency across the global OTC industry [10]

Core Viewpoint - The announcement of the completion of the ETHK building marks a significant strategic shift for the company towards becoming a leader in the Real World Assets (RWA) digitalization space, supported by a new brand identity that reflects its commitment to blockchain technology and compliance [2][4][10]. Group 1: Strategic Infrastructure - The ETHK building is the world's first core base focused on RWA digital technology research and ecosystem empowerment, located in Nanjing with a total area of approximately 70,000 square meters [3][4]. - The building serves a dual purpose: as a physical base for research and collaborative innovation, and as a trusted technology development and output hub, expected to gather over 5,000 technical experts and R&D engineers [4][5]. Group 2: RWA Ecosystem Layout - The recent logo update and building completion represent the company's "second entrepreneurship," fully transitioning towards the RWA sector, which involves the tokenization of real-world assets [5][6]. - The RWA market is projected to reach a total locked value (TVL) of $12.5 billion by June 2025, reflecting a 124% increase from 2024, with a global market size expected to hit $16.1 trillion by 2030 [5][6]. Group 3: Innovative Business Model - The company has established a strategic partnership with Renhe Pharmaceutical to create the world's first OTC vertical RWA exchange, showcasing its innovative "exchange within an exchange" model [6][7]. - This model aims to provide on-chain financial infrastructure for leading enterprises across various industries, facilitating the tokenization of intangible assets and enhancing global asset flow [7][8]. Group 4: Value Creation and Market Impact - The company's RWA strategy aims to create multidimensional value, contributing to national strategies and public welfare, while enhancing the global OTC industry's digital transformation [8][9]. - The strategic collaboration with Renhe Pharmaceutical is expected to optimize asset structures and enable the introduction of innovative OTC products from global markets into China, benefiting both companies and consumers [8][9].